Dr. Reddy’s Profit Falls 32%, Signals Pharma Restructuring

Hyderabad’s pharmaceutical giant, Dr. Reddy’s Laboratories, reported a 32% decline in its second‑quarter net profit, falling to ₹913 crore, as revenue from operations slipped to ₹8,697.8 crore. The downturn was attributed to a combination of lower sales volumes and a slowdown in the domestic market, compounded by currency fluctuations that eroded margins. The company’s earnings per share dipped accordingly, prompting analysts to reassess its growth trajectory for the year.

The decline came at a time when the Indian pharmaceutical sector was facing increased competition from generic manufacturers and pressure from global pricing regulations. Dr. Reddy’s, which has long relied on a diversified portfolio of branded and generic drugs, found its market share eroding in key therapeutic segments. The company’s management acknowledged the need to streamline operations and invest in research to counteract the competitive squeeze.

In response, the company announced a restructuring plan that will cut costs by 15% over the next fiscal year and redirect capital toward high‑margin specialty drugs. The move is expected to stabilize earnings and restore investor confidence. In the broader market, the announcement has prompted a reevaluation of valuation multiples for Indian pharma stocks, as analysts weigh the sector’s resilience against the backdrop of global pricing pressures.